The present disclosure relates to a viable cell population, a method for production and uses thereof. The viable cell population of the present disclosure can be used in medicine, in particular in a method for the treatment of cancer, immune diseases, or viral or bacterial infections. This disclosure may also be suitable for cellular vaccine development. The viable cell population now disclosed has low sialic acid content, is loaded with specific antigens, shows higher antigen presentation, high maturation and co-stimulatory properties, and less tolerogenic properties. The present disclosure relates to a population of viable cells, wherein said population is obtainable by the maturation of the dendritic cells or T2 cells treated with sialidase during 45 min - overnight at 37 °C and, wherein the sialidase concentration vary between 0.002 U/mL - 0.005 U/mL per 1x106 of dendritic cells or T2 cells.
|IPC||C12N 5/ 0784 A I, A61K35/15|
|Publication status||Published - 5 Jan 2017|